Manuscripts submitted to Acta Pharmaciae Indonesia undergo an Initial Review by the Editorial Board. This initial assessment evaluates the article's alignment with the journal's scope, originality, novelty, sufficiency of experimental data, ethical considerations, clarity of structure and language, and formatting. Manuscripts failing to meet these standards are either returned to the author for revision or rejected without further review.

Those manuscripts that pass the Initial Review are then subjected to a double-blind peer review process, with at least two reviewers assigned. This ensures the anonymity of both authors and reviewers throughout the evaluation.

Strict confidentiality is maintained for all manuscripts under review. Reviewers are forbidden from sharing the manuscript, using its content for personal gain, or uploading any part of it to generative AI tools. They must also declare any conflicts of interest and decline to review if such conflicts exist.

Upon completion of the peer review, the assigned editor makes a decision. If revisions are required, the manuscript is returned to the authors. Following resubmission, the editor makes the final decision (acceptance or rejection). Peer reviewers are rated on both the substantial and technical aspects of each manuscript they evaluate.

Authors may suggest potential reviewers in their cover letter. Journal editors will screen these recommendations for conflicts of interest and will not contact individuals with competing interests. Reviewers are also required to declare any conflicts of interest themselves. During initial submission, authors may also list individuals they wish to exclude from consideration as peer reviewers. The editorial team will honor these requests, provided they do not impede an objective and thorough assessment of the submission. Peer reviewer assignments are based on their expertise and experience in research and publication relevant to the manuscript's field.